Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Astrazeneca (AZNCF) Cash & Current Investments (2016 - 2025)

Historic Cash & Current Investments for Astrazeneca (AZNCF) over the last 17 years, with Q4 2025 value amounting to $7.9 billion.

  • Astrazeneca's Cash & Current Investments rose 1143.26% to $7.9 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $7.9 billion, marking a year-over-year increase of 1143.26%. This contributed to the annual value of $7.9 billion for FY2025, which is 1143.26% up from last year.
  • Astrazeneca's Cash & Current Investments amounted to $7.9 billion in Q4 2025, which was up 1143.26% from $10.1 billion recorded in Q3 2025.
  • Astrazeneca's Cash & Current Investments' 5-year high stood at $16.6 billion during Q2 2021, with a 5-year trough of $5.5 billion in Q3 2022.
  • Moreover, its 5-year median value for Cash & Current Investments was $7.0 billion (2022), whereas its average is $7.8 billion.
  • In the last 5 years, Astrazeneca's Cash & Current Investments skyrocketed by 21822.27% in 2021 and then crashed by 6429.47% in 2022.
  • Astrazeneca's Cash & Current Investments (Quarter) stood at $6.4 billion in 2021, then decreased by 0.11% to $6.4 billion in 2022, then fell by 6.92% to $6.0 billion in 2023, then rose by 19.42% to $7.1 billion in 2024, then rose by 11.43% to $7.9 billion in 2025.
  • Its Cash & Current Investments was $7.9 billion in Q4 2025, compared to $10.1 billion in Q3 2025 and $8.9 billion in Q2 2025.